BACKGROUND: Drug eluting stent (DES) failure including restenosis and stent thrombosis, or disease progression may result in target vessel revascularization (TVR) but the relative contribution of these mechanisms in the DES era is not well described. We sought to examine the predictors and presentations of patients with clinically driven TVR after DES. METHODS: Patients with all lesions treated with a DES in the Dynamic Registry from 2004 to 2006 were analyzed. Included were 2691 patients with 3401 lesions. Patients with and without incident clinically driven TVR at 2years were compared according to baseline clinical, procedural, and angiographic characteristics and independent predictors of TVR and target lesion revascularization (TLR) were determined by multivariate analysis. RESULTS: By 2-years, TVR occurred in 7.2% of patients and TLR in 3.8%, with 71.6% and 82.5% of repeat revascularization events occurring in the first year, respectively. The indication for first TVR was myocardial infarction in 18.6% (n=34), unstable angina in 42.6% (n=78), stable coronary disease in 25.7% (n=47) and other/unknown in 13.1% (n=24). Disease progression was responsible for 47% of TVR. Among patients with TLR, restenosis was the mechanism in 86.6% and stent thrombosis in 13.4%. Independent predictors of TVR included younger age, diabetes, attempted graft lesion, lesion length >30mm and prior lesion intervention. Independent predictors of TVR and TLR were similar. CONCLUSION: The incidence of clinically driven TVR is low in patients treated with DES and nearly half is attributable to disease progression, which along with the low rate of in-stent restenosis explains why the mode of presentation is often an acute coronary syndrome.
BACKGROUND: Drug eluting stent (DES) failure including restenosis and stent thrombosis, or disease progression may result in target vessel revascularization (TVR) but the relative contribution of these mechanisms in the DES era is not well described. We sought to examine the predictors and presentations of patients with clinically driven TVR after DES. METHODS:Patients with all lesions treated with a DES in the Dynamic Registry from 2004 to 2006 were analyzed. Included were 2691 patients with 3401 lesions. Patients with and without incident clinically driven TVR at 2years were compared according to baseline clinical, procedural, and angiographic characteristics and independent predictors of TVR and target lesion revascularization (TLR) were determined by multivariate analysis. RESULTS: By 2-years, TVR occurred in 7.2% of patients and TLR in 3.8%, with 71.6% and 82.5% of repeat revascularization events occurring in the first year, respectively. The indication for first TVR was myocardial infarction in 18.6% (n=34), unstable angina in 42.6% (n=78), stable coronary disease in 25.7% (n=47) and other/unknown in 13.1% (n=24). Disease progression was responsible for 47% of TVR. Among patients with TLR, restenosis was the mechanism in 86.6% and stent thrombosis in 13.4%. Independent predictors of TVR included younger age, diabetes, attempted graft lesion, lesion length >30mm and prior lesion intervention. Independent predictors of TVR and TLR were similar. CONCLUSION: The incidence of clinically driven TVR is low in patients treated with DES and nearly half is attributable to disease progression, which along with the low rate of in-stent restenosis explains why the mode of presentation is often an acute coronary syndrome.
Authors: D O Williams; R Holubkov; W Yeh; M G Bourassa; M Al-Bassam; P C Block; P Coady; H Cohen; M Cowley; G Dorros; D Faxon; D R Holmes; A Jacobs; S F Kelsey; S B King; R Myler; J Slater; V Stanek; H A Vlachos; K M Detre Journal: Circulation Date: 2000-12-12 Impact factor: 29.690
Authors: Ruchira Glaser; Faith Selzer; David P Faxon; Warren K Laskey; Howard A Cohen; James Slater; Katherine M Detre; Robert L Wilensky Journal: Circulation Date: 2004-12-27 Impact factor: 29.690
Authors: Joachim Schofer; Michael Schlüter; Anthony H Gershlick; William Wijns; Eulogio Garcia; Erick Schampaert; Günter Breithardt Journal: Lancet Date: 2003-10-04 Impact factor: 79.321
Authors: A Kastrati; A Schömig; S Elezi; H Schühlen; J Dirschinger; M Hadamitzky; A Wehinger; J Hausleiter; H Walter; F J Neumann Journal: J Am Coll Cardiol Date: 1997-11-15 Impact factor: 24.094
Authors: Mandeep Singh; Bernard J Gersh; Robyn L McClelland; Kalon K L Ho; James T Willerson; William F Penny; David R Holmes Journal: Circulation Date: 2004-06-01 Impact factor: 29.690
Authors: Pedro A Lemos; Angela Hoye; Dick Goedhart; Chourmouzios A Arampatzis; Francesco Saia; Willem J van der Giessen; Eugene McFadden; Georgios Sianos; Pieter C Smits; Sjoerd H Hofma; Pim J de Feyter; Ron T van Domburg; Patrick W Serruys Journal: Circulation Date: 2004-03-01 Impact factor: 29.690
Authors: Maayan Konigstein; Mahesh V Madhavan; Ori Ben-Yehuda; Hussein M Rahim; Iva Srdanovic; Fotis Gkargkoulas; Ghazaleh Mehdipoor; Evan Shlofmitz; Akiko Maehara; Björn Redfors; Ankita K Gore; Thomas McAndrew; Gregg W Stone; Ziad A Ali Journal: Am Heart J Date: 2019-04-12 Impact factor: 4.749
Authors: Alexander C Fanaroff; Pearl Zakroysky; Daniel Wojdyla; Lisa A Kaltenbach; Matthew W Sherwood; Matthew T Roe; Tracy Y Wang; Eric D Peterson; Hitinder S Gurm; Mauricio G Cohen; John C Messenger; Sunil V Rao Journal: Circulation Date: 2019-01-22 Impact factor: 29.690